TW200819446A - Maleate, tosylate, fumarate, and oxalate salts of 5-(1(s)-amino-2-hydroxyethyl)-n-[(2,4-difluorophenyl)-methyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinoline]-4-oxazolecarboxamide and preparation process therefor - Google Patents

Maleate, tosylate, fumarate, and oxalate salts of 5-(1(s)-amino-2-hydroxyethyl)-n-[(2,4-difluorophenyl)-methyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinoline]-4-oxazolecarboxamide and preparation process therefor Download PDF

Info

Publication number
TW200819446A
TW200819446A TW096130026A TW96130026A TW200819446A TW 200819446 A TW200819446 A TW 200819446A TW 096130026 A TW096130026 A TW 096130026A TW 96130026 A TW96130026 A TW 96130026A TW 200819446 A TW200819446 A TW 200819446A
Authority
TW
Taiwan
Prior art keywords
compound
formula
salt
crystalline
salt form
Prior art date
Application number
TW096130026A
Other languages
English (en)
Chinese (zh)
Inventor
Xiao-Ming Chen
Xiao Chen
Jianguo Yin
Xiaoyong Fu
David J Blythin
Rongze Kuang
Ho-Jane Shue
Scott Trzaska
Chee-Wah Tang
Vincenzo Liotta
Zaher Shabani
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38895795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200819446(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of TW200819446A publication Critical patent/TW200819446A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW096130026A 2006-08-14 2007-08-14 Maleate, tosylate, fumarate, and oxalate salts of 5-(1(s)-amino-2-hydroxyethyl)-n-[(2,4-difluorophenyl)-methyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinoline]-4-oxazolecarboxamide and preparation process therefor TW200819446A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83766106P 2006-08-14 2006-08-14

Publications (1)

Publication Number Publication Date
TW200819446A true TW200819446A (en) 2008-05-01

Family

ID=38895795

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096130026A TW200819446A (en) 2006-08-14 2007-08-14 Maleate, tosylate, fumarate, and oxalate salts of 5-(1(s)-amino-2-hydroxyethyl)-n-[(2,4-difluorophenyl)-methyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinoline]-4-oxazolecarboxamide and preparation process therefor

Country Status (11)

Country Link
US (1) US7956189B2 (enExample)
EP (1) EP2069337A1 (enExample)
JP (3) JP2010500406A (enExample)
CN (1) CN101522671A (enExample)
AR (1) AR062373A1 (enExample)
CA (1) CA2660703A1 (enExample)
CL (1) CL2007002366A1 (enExample)
MX (1) MX2009001770A (enExample)
PE (1) PE20080424A1 (enExample)
TW (1) TW200819446A (enExample)
WO (1) WO2008021271A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
JP2015524400A (ja) * 2012-07-19 2015-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 9−[4−(3−クロロ−2−フルオロ−フェニルアミノ)−7−メトキシ−キナゾリン−6−イルオキシ]−1,4−ジアザ−スピロ[5.5]ウンデカン−5−オンのフマル酸塩、その薬物としての使用及び調製
CN111135171B (zh) 2013-01-23 2023-09-08 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
CN112714762A (zh) * 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE531705T1 (de) * 2004-05-18 2011-11-15 Schering Corp Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren

Also Published As

Publication number Publication date
CA2660703A1 (en) 2008-02-21
US7956189B2 (en) 2011-06-07
EP2069337A1 (en) 2009-06-17
WO2008021271A1 (en) 2008-02-21
MX2009001770A (es) 2009-02-25
JP2012176989A (ja) 2012-09-13
JP2013032394A (ja) 2013-02-14
JP2010500406A (ja) 2010-01-07
PE20080424A1 (es) 2008-04-28
US20080108818A1 (en) 2008-05-08
CL2007002366A1 (es) 2008-03-14
AR062373A1 (es) 2008-11-05
CN101522671A (zh) 2009-09-02

Similar Documents

Publication Publication Date Title
AU2023202085B2 (en) Polymorphic forms of RAD1901-2HCL
CN105143194B (zh) 依洛昔巴特的结晶修饰物
TWI379681B (en) Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
CN107873029B (zh) 依鲁替尼与羧酸的共晶体
US9610278B2 (en) Glycopyrrolate salts
TW202019914A (zh) 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式
JP2013032394A (ja) 5−(1(s)−アミノ−2−ヒドロキシエチル)−n−[(2,4−ジフルオロフェニル)−メチル]−2−[8−メトキシ−2−(トリフルオロメチル)−5−キノリン]−4−オキサゾールカルボキサミドの塩
US11291651B2 (en) Glycopyrrolate salts
BR122018014454B1 (pt) forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
JP5899214B2 (ja) 4−[−2−[[5−メチル−1−(2−ナフタレニル)−1h−ピラゾール−3−イル]オキシ]エチル]モルホリン塩酸塩の固体形態
JP6691218B2 (ja) 選択的なs1p1受容体アゴニストの新規な結晶形及びその製造方法
WO2014082354A1 (zh) 西达本胺的晶型及其制备方法与应用
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
TW202033508A (zh) 貝前列素-314d晶體及其製備方法
KR20250130412A (ko) 화합물 a의 염과 결정형, 및 그 제조 방법과 용도
JP2019518058A (ja) スピロ−オキシインドール化合物の固体状態形
EA036295B1 (ru) Твердые формы замещенных 5,6-дигидро-6-фенилбензо[f]изохинолин-2-аминовых соединений
TWI724651B (zh) 貝前列素-314d單水合物晶體及其製備方法
JP7152122B2 (ja) エダラボン塩
TW201143761A (en) Tablet formulation of ezatiostat
TW201018660A (en) Chemical process
WO2021030843A1 (en) Solid-state forms of abemaciclib, their use and preparation
TW202140493A (zh) 2-吲哚啉螺環酮類化合物或其鹽、溶劑錯合物之非晶形式或結晶形式
US20220233500A1 (en) Glycopyrrolate salts
JP2025510061A (ja) 縮合三環式誘導体又はその薬学的に許容される塩の結晶